Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that the results from the open label Phase 2 PROSPECT Study of tirabrutinib is to be ...

Primary extranodal marginal zone lymphomas (EMZL ... Immunohistochemical stains found a marked increase in CD20 B cells with Ki-67 <5%. Postoperative positron emission tomography was negative for ...

Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The investigation demonstrated that dual targeting of DOT1L and EZH2 effectively prevented human GCB-DLBCL xenograft growth in vivo. According to the authors, GCB-DLBCLs exhibit strong dependence on ...

Most clinical trials test new treatments only after cancer has relapsed and grown large enough to be detected on scans. The ...

The presence of lymphoma can worsen liver damage in PBC and significantly accelerate the progression of liver disease.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

An "armored" CAR T cell therapy engineered to secrete interleukin-18 (IL 18) demonstrated cancer reduction in 81% and complete remission in 52% of patients with treatment-resistant B-cell lymphomas.